Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy

The British Journal of Psychiatry : the Journal of Mental Science
Linda DaviesCUtLASS team

Abstract

There are claims that the extra costs of atypical (second-generation) antipsychotic drugs over conventional (first-generation) drugs are offset by improved health-related quality of life. To determine the relative costs and value of treatment with conventional or atypical antipsychotics in people with schizophrenia. Cost-effectiveness acceptability analysis integrated clinical and economic randomised controlled trial data of conventional and atypical antipsychotics in routine practice. Conventional antipsychotics had lower costs and higher quality-adjusted life-years (QALYs) than atypical antipsychotics and were more than 50% likely to be cost-effective. The primary and sensitivity analyses indicated that conventional antipsychotics may be cost-saving and associated with a gain in QALYs compared with atypical antipsychotics.

References

Apr 1, 1991·Statistics in Medicine·D B Rubin, N Schenker
Jan 1, 1984·Schizophrenia Bulletin·D W HeinrichsW T Carpenter
Sep 15, 1995·Statistics in Medicine·P W LavoriD Shera
Aug 1, 1995·The British Journal of Oral & Maxillofacial Surgery·A AliD W Patton
Mar 17, 2001·Health Economics·A H Briggs, B J O'Brien
Aug 22, 2001·European Psychiatry : the Journal of the Association of European Psychiatrists·J LynchJ S Hellewell
Jan 31, 2002·The Journal of Clinical Psychiatry·M LewisS Frangou
May 1, 2002·International Clinical Psychopharmacology·M KnappA David
Sep 17, 2002·European Psychiatry : the Journal of the Association of European Psychiatrists·L Hosák, R Bahbouh
Dec 31, 2002·Archives of Medical Research·Cynthia S PalmerDennis A Revicki
May 21, 2003·Acta Psychiatrica Scandinavica. Supplementum·L PrietoUNKNOWN SOHO Study Group
Aug 20, 2003·Health Technology Assessment : HTA·A-M BagnallJ Kleijnen
Dec 4, 2003·JAMA : the Journal of the American Medical Association·Robert RosenheckUNKNOWN Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine
Jul 24, 2004·BMJ : British Medical Journal·Michael D Rawlins, Anthony J Culyer
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Feb 7, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·J BobesM Bousoño
Jan 1, 2005·International Journal of Psychiatry in Clinical Practice·Helen M LloydThomas R E Barnes

❮ Previous
Next ❯

Citations

Dec 9, 2008·Lancet·Peter Tyrer, Tim Kendall
Sep 11, 2009·Psychological Medicine·Shôn Lewis
May 3, 2008·Psychiatric Services : a Journal of the American Psychiatric Association·Marisa Elena Domino, Marvin S Swartz
Jul 26, 2012·Health Economics Review·Antonio J García-RuizMiguel A Casado
Sep 11, 2008·Pharmacogenomics·Bk ThelmaArun Kumar Tiwari
Feb 20, 2013·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Simon FreyTom Stargardt
Jun 3, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Jan Scott
Jun 2, 2010·The British Journal of Psychiatry : the Journal of Mental Science·Nicolas A CrossleyPaddy Power
Nov 18, 2008·International Review of Psychiatry·Naotaka Shinfuku, Chay-Hoon Tan
May 23, 2009·Journal of Intellectual Disability Research : JIDR·R RomeoP Oliver-Africano
Jun 28, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Taehwan Park, Karen M Kuntz
Jan 29, 2008·Expert Opinion on Pharmacotherapy·Nitin Gogtay, Judith Rapoport
Feb 19, 2015·Health Technology Assessment : HTA·Karl ClaxtonMark Sculpher
Feb 24, 2010·Journal of Psychopharmacology·Katherine J AitchisonPaul McCrone
Jul 3, 2016·The Cochrane Database of Systematic Reviews·James R SampfordVivek A Furtado
Jul 10, 2014·The Cochrane Database of Systematic Reviews·Magdolna TardyStefan Leucht
Jan 15, 2014·The Cochrane Database of Systematic Reviews·Kai KochVivek A Furtado
Jan 17, 2015·The Cochrane Database of Systematic Reviews·Markus DoldStefan Leucht
May 23, 2015·The Cochrane Database of Systematic Reviews·Mike SkeltonSimon P Thacker
Aug 15, 2012·Molecular Psychiatry·W T Carpenter, J M Davis
Jul 23, 2009·Health Affairs·Robert A Rosenheck, Michael J Sernyak
Jun 13, 2018·The Cochrane Database of Systematic Reviews·Hosam E MatarStephanie J Sampson
Jun 11, 2014·The Cochrane Database of Systematic Reviews·Jataveda MahapatraClive E Adams
Dec 6, 2008·Journal of Psychiatric Practice·Anand K Pandurangi, Alican Dalkilic
Feb 27, 2019·Health Technology Assessment : HTA·Anthony P MorrisonDavid Kingdon
Mar 13, 2008·Epidemiologia e psichiatria sociale·Martin Knapp, Roshni Mangalore
Mar 10, 2015·The Cochrane Database of Systematic Reviews·Benno HartungStefan Leucht
Apr 15, 2016·The Cochrane Database of Systematic Reviews·Stephanie SampsonJohn M Davis
Mar 4, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Shôn Lewis, Jeffrey Lieberman
Apr 8, 2010·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·George Foussias, Gary Remington
Apr 1, 2020·Irish Journal of Psychological Medicine·R RowntreeL Feeney
Apr 9, 2009·Cost Effectiveness and Resource Allocation : C/E·Nicolas M FuriakSteven D Culler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here